Stem Cell Transplant for Immunologic or Histiocytic Disorders
This trial is active, not recruiting.
|Conditions||hemophagocytic lymphohistiocytosis, x-linked lymphoproliferative disorders, chediak-higashi syndrome, griscelli syndrome, immunologic deficiency syndromes, langerhans-cell histiocytosis|
|Treatments||stem cell transplant, fludarabine, melphalan, atg or campath|
|Sponsor||Masonic Cancer Center, University of Minnesota|
|Start date||August 2002|
|End date||August 2012|
|Trial size||30 participants|
|Trial identifier||NCT00176865, 0207M29448, MT2002-12|
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic or histiocytic disorders. The researchers hypothesize that this regimen will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD).
Patients will be randomized biologically into one of 3 arms based upon donor availability: (a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
To demonstrate the safety and the ability to establish stable mixed chimerism (>10% donor cells at day 100) using a nonmyeloablative preparative regimen in a phase 2 pilot trial
time frame: Day 100
Determine the incidence of chimerism at 100 days, 6 months and 1 year
time frame: 100 days, 6 months and 1 year
Determine the incidence of grade 2-4 and 3-4 acute graft versus host disease (aGVHD)
time frame: Day 100
Determine the incidence of chronic graft versus host disease (cGVHD)
time frame: 6 months and 1 year
Compare quality of life (QOL)
time frame: Pretransplant, 1 year, 2 years and 5 years
Determine overall survival
time frame: Day 100 and 1 year
Male or female participants up to 35 years old.
Inclusion Criteria: Patients with immunodeficiencies or histiocytic disorders 0-35 years of age with an acceptable stem cell donor and disease characteristic defined by the following: - Patients with histocytic disorders (hemophagocytic lymphohistiocytosis of any etiology and refractory Langerhans cell histiocytosis) who do not meet eligibility criteria for a myeloablative transplant procedure - Patients with immunodeficiency disorders in whom residual immune function may not require a fully myeloablative preparative regimen or patient is ineligible for standard myeloablative preparative regimen (any form of severe combined immunodeficiency [SCID], or other immunodeficiency with T cell defect) - Patients with immunodeficiency disorders that have had poor outcome with myeloablative stem cell transplants (including, but not limited to, common variable immunodeficiency [CVID], Wiskott Aldrich Syndrome [WAS] if > 5 years of age, ataxia telangiectasia) - Patients with immunodeficiencies or histocytic disorders that require a second stem cell transplant (SCT) for any reason Exclusion Criteria: - Karnofsky or Lansky performance score <70 - Glomerular filtration rate (GFR)<30% predicted - Cardiac function <50% normal by echocardiogram - Serum creatinine > 2x normal for age/weight - Pregnant or lactating females - Active serious infection that has not had an adequate course of therapy pre-SCT. Any patient with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC) or human immunodeficiency virus (HIV) seropositivity
|Official title||Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism|
|Principal investigator||Angela Smith, MD|
|Description||Prior to transplantation, subjects will receive Melphalan, Fludarabine and Anti-Thymocyte Globulin (ATG) or Campath. These three drugs are being given to subjects to help the new stem cells take and grow. On the day of transplantation, subjects will receive stem cells transfused via intravenous (IV) catheter. After stem cell transplantation, subjects will be given Cyclosporin A (CsA) and mycophenolate mofetil (MMF) to reduce the risk of graft-versus-host disease, the complication that occurs when the donor's stem cells react against the patient.|
Call for more information